Next Article in Journal
Specificity of CD8+ T-Cell Responses Following Vaccination with Conserved Regions of HIV-1 in Nairobi, Kenya
Previous Article in Journal
Protective Efficacy of a Chimeric Insect-Specific Flavivirus Vaccine against West Nile Virus
Open AccessArticle

Intranasal Therapeutic Peptide Vaccine Promotes Efficient Induction and Trafficking of Cytotoxic T Cell Response for the Clearance of HPV Vaginal Tumors

1
UTHealth Graduate School of Biomedical Sciences at Houston, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
2
School of Medicine, University of Puerto Rico, San Juan, PR 00921, USA
3
Department of Thoracic Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
*
Author to whom correspondence should be addressed.
Vaccines 2020, 8(2), 259; https://doi.org/10.3390/vaccines8020259
Received: 1 May 2020 / Revised: 18 May 2020 / Accepted: 27 May 2020 / Published: 29 May 2020
(This article belongs to the Section Human Papillomavirus Vaccines)
Human papillomavirus (HPV)-induced cancers continue to affect millions of women around the world, and the five year survival rate under the current standard of care for these cancers is less than 60% in some demographics. Therefore there is still an unmet need to develop an effective therapy that can be easily administered to treat established HPV cervical cancer lesions. We sought to investigate the potential of an intranasal HPV peptide therapeutic vaccine incorporating the combination of α-Galactosylceramide (α-GalCer) and CpG-ODN adjuvants (TVAC) against established HPV genital tumors in a syngeneic C57BL/6J mouse model. We obtained evidence to show that TVAC, delivered by the mucosal intranasal route, induced high frequencies of antigen-specific CD8 T cells concurrent with significant reduction in the immunosuppressive regulatory T cells and myeloid derived suppressor cells in the tumor microenvironment (TME), correlating with sustained elimination of established HPV genital tumors in over 85% of mice. Inclusion of both the adjuvants in the vaccine was necessary for significant increase of antigen-specific CD8 T cells to the tumor and antitumor efficacy because vaccination incorporating either adjuvant alone was inefficient. These results strongly support the utility of the TVAC administered by needle-free intranasal route as a safe and effective strategy for the treatment of established genital HPV tumors. View Full-Text
Keywords: human papillomavirus; therapeutic vaccine; adjuvants; intranasal immunization; mucosal immunity human papillomavirus; therapeutic vaccine; adjuvants; intranasal immunization; mucosal immunity
Show Figures

Figure 1

MDPI and ACS Style

Sierra, G.; Dorta-Estremera, S.; Hegde, V.L.; Nookala, S.M.K.; Yanamandra, A.V.; Sastry, K.J. Intranasal Therapeutic Peptide Vaccine Promotes Efficient Induction and Trafficking of Cytotoxic T Cell Response for the Clearance of HPV Vaginal Tumors. Vaccines 2020, 8, 259.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop